References

  1. Merino-Ramírez MÁ, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. 
    Can J Neurol Sci. 2016;43(5):635-647.
  2. Eaton LM, Lambert EH. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc. 1957;163(13):1117-1124.
  3. Harms L, Sieb JP, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521-530.
  4. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. 
    Lancet Neurol. 2011;10(12):1098-1107.
  5. Jacob S, Muppidi S, Guidon A, et al; International MG/COVID-19 Working Group. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803.
  6. Muppidi S, Wolfe GI, Barohn RJ. Diseases of the neuromuscular junction. In: Swaiman K, Ashwal S, Ferriero D, Schor N, eds.
    Pediatric Neurology: Principles and Practice. 5th ed. Philadelphia, PA: Elsevier; 2011:1549-1569.
  7. Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann NY Acad Sci. 2003;998:500-508.
  8. Tarr TB, Wipf P, Meriney SD. Synaptic pathophysiology and treatment of Lambert-Eaton myasthenic syndrome. Mol Neurobiol. 2015;52(1):456-463.
  9. Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol. 1996;40:739-749.
  10. Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. TINS. 1989;12(12):496-502.
  11. National Organization for Rare Disorders (NORD) website. Rare disease database: Lambert-Eaton myasthenic syndrome. Accessed April 22, 2021. https://rarediseases.org/rare-diseases/lambert-eaton-myasthenic-syndrome/.
  12. Maddison P, Lang B, Mill K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer.
    J Neurol Neurosurg Psychiatry. 2001;70:212-217.
  13. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359-363.
  14. Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011;2011:973808.
  15. Angelini C, Martignago S, Biscigli M, Albertini E. Myasthenia gravis with anti-MuSK antibodies: clinical features and histopathological changes. In: Pruitt JA, ed. A Look into Myasthenia Gravis. InTech; 2012:1-14. Accessed June 14, 2021, https://www.intechopen.com/books/a-look-into-myasthenia-gravis/myasthenia-gravis-with-anti-musk-antibodies-clinical-features-and-histopathological-changes.
  16. Mantegazza R, Bernasconi P. Inflammatory myopathies: dermatomyositis, polymyositis and inclusion body myositis. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013. Accessed June 14, 2021. https://www.ncbi.nlm.nih.gov/books/NBK6196/.
  17. Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am. 2013;24(1):193-207.
  18. Institute of Medicine (US) Committee on Multiple Sclerosis: Current Status and Strategies for the Future. Characteristics and management of major symptoms. In: Joy JE, Jonston RB Jr, eds. Multiple Sclerosis: Current Status and Strategies for the Future. Washington, DC: National Academies Press (US); 2001; 115-176.
  19. De Biagi F, Heikkola LM, Nordio S, Ruhaak L. Update on recent developments in communication and swallowing in multiple sclerosis. 
    Int J MS Care. 2020;22(6):270-275.
  20. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727.
  21. Zalewski NL, Lennon VA, Lachance DH, et al. P/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments. Muscle Nerve. 2016;54(2):220-227.
  22. Lennon VA. Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology. 1997;48(suppl 5):S23-S27.
  23. Data on file, Catalyst Pharmaceuticals.
  24. Patel P, Pobre T. Electrodiagnostic evaluation of neuromuscular junction disorder. In: StatPearls [Internet]. StatPearls Publishing; 2021. Updated September 10, 2020. Accessed August 27, 2021. https://www.ncbi.nlm.nih.gov/books/NBK562302/.
  25. Cherian A, Baheti NN, Iype T. Electrophysiological study in neuromuscular junction disorders. Ann Indian Acad Neurol. 2013;16(1):34-41.
  26. Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2008;37(5):572-575.
  27. Ivanovski T, Miralles F. Lambert-Eaton myasthenic syndrome: early diagnosis is key. Degener Neurol Neuromuscul Dis. 2019;9:27-37.
  28. Farrugia ME. Myasthenic syndromes. J R Coll Physicians Edinb. 2011;41(1):43-47; quiz 48.
  29. Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol. 2017;264(9):1854-1863.
  30. Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest. 2003;123(suppl 1):97S-104S.
  31. Quartel A, Turbeville S, Lounsbury D. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Curr Med Res Opin. 2010;26(6):1363-1375.
  32. Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. ClinPharmacolTher. 2009;86(1):44-48.
  33. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678-683. 
  34. Chalk CH, Murray NM, Newsom-Davis J, O’Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990;40(10):1552-1556.
  35. Weingarten TN, Araka CN, Mogensen ME, et al. Lambert-Eaton myasthenic syndrome during anesthesia: a report of 37 patients.
    J Clin Anesth.     2014;26(8):648-653.
  36. Stickler DE, et al. Which medications should be avoided in the treatment of Lambert-Eaton myasthenic syndrome (LEMS)? Medscape. Accessed January 12, 2023. https://www.medscape.com/answers/1170810-90751/which-medications-should-be-avoided-in-the-treatment-of-lambert-eaton-myasthenic-syndrome-lems.
  37. Harnett MT, Chen W, Smith SM. Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness. Neuropharmacology. 2009;57(5-6):502-505.
  38. Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011;34(10):839-847.
  39. Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570-2581.
  40. Small S, Ali HH, Lennon VA, Brown RH, Carr DB, deArmendia A. Anesthesia for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma. Anesthesiology. 1992;76(1):142-145.
  41. Anderson CJ, Guidon AC, Khan FB, et al. Case report of Lambert Eaton myasthenic syndrome in a patient with small cell lung cancer on immune checkpoint inhibitor therapy. OBM Neurobiol. 2021;5(1):1-9.
  42. Lipka AF, Boldingh MI, van Zwet EW, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2020;94(5):e511-e520.
  43. Titulaer MJ, Wirtz PW, Willems LNA, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276-4281.
  44. Kanaji N, Watanabe N, Kita N, et al. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol. 2014;5(3):197-223.
  45. Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compre Canc Netw. 2006;4(6):631-638.
  46. Soomro Z, Youssef M, Yust-Katz S, Jalai A, Patel AJ, Mandel J. Paraneoplastic syndromes in small cell lung cancer. J Thorac Dis. 2020;12(10):6253-6263.
  47. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-1140. 
  48. Maddison P, Lipka AF, Gozzard P, et al. Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort. Sci Rep. 2020;10(1):10546.
  49. Yoon CH, Owusu-Guha J, Smith A, Buschur P. Amifampridine for the management of Lambert-Eaton myasthenic syndrome: a new take on an old drug. Ann Pharmacother. 2020;54(1):56-63.
  50. Full Prescribing Information for FIRDAPSE (amifampridine). Catalyst Pharma; 2022.
  51. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902-908.
  52. Wirtz PW, Wintzen AR, Verschuuren JJ. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve. 2005;32(2):226-229.
  53. Titulaer MJ, Wirtz PW, Kuks JBM, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients.
    J Neuroimmunol. 2008;201:153-158.